PT - JOURNAL ARTICLE AU - Mascarenhas, Rumika AU - Merrikh, Daria AU - Khanbabaei, Maryam AU - Kaur, Navprabhjot AU - Ghaderi, Navid AU - Maroilley, Tatiana AU - Liu, Yiping AU - Soule, Tyler AU - Appendino, Juan Pablo AU - Jacobs, Julia AU - Wiebe, Samuel AU - , AU - Hader, Walter AU - Pfeffer, Gerald AU - Tarailo-Graovac, Maja AU - Klein, Karl Martin TI - Detecting somatic variants in purified brain DNA obtained from surgically implanted depth electrodes in epilepsy AID - 10.1101/2024.07.08.24310005 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.08.24310005 4099 - http://medrxiv.org/content/early/2024/07/17/2024.07.08.24310005.short 4100 - http://medrxiv.org/content/early/2024/07/17/2024.07.08.24310005.full AB - Somatic variants causing epilepsy are challenging to detect as they are only present in a subset of brain cells (e.g., mosaic) resulting in low variant allele frequencies. Traditional methods that rely on surgically resected brain tissue are limited to patients undergoing brain surgery. We developed an improved protocol to detect somatic variants using DNA from stereo-electroencephalography (SEEG) depth electrodes, enabling access to a larger patient cohort and diverse brain regions. This protocol mitigates issues of cell contamination and low yields by purifying neuronal nuclei using fluorescence-activated nuclei sorting. Furthermore, we employed advanced amplification techniques, stringent quality control and an optimized bioinformatic workflow to decrease false positives. Using digital droplet polymerase chain reaction, we confirmed all four selected candidate somatic variants. Our approach enhances the reliability and applicability of SEEG-derived DNA for epilepsy, offering insights into its molecular basis, facilitating identification of the epileptogenic zone and other advancements in precision medicine.Competing Interest StatementNone of the authors has any conflict of interest to disclose.Funding StatementThis project has been made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada) and Brain Canada, and by the Azrieli Foundation. It was also supported by Epilepsy Canada, doing business as Epilepsy Canada. The 202 unrelated germline samples were sequenced within the RAISE-GENIC project (Rational antiepileptic drug selection by combining gene network and ICT analysis), funded by the Canadian Institutes of Health Research (CIHR), under the frame of ERA PerMed. KMK also received support from the Department of Clinical Neurosciences, Hotchkiss Brain Institute and Alberta Children’s Hospital Research Institute, University of Calgary. M.T-G was supported by the Alberta Children’s Hospital Foundation and the CIHR-Bridge grant number OGB-185746. Infrastructure in the laboratory of GP was supported by a Canada Foundation for Innovation Grant (John R. Evans Leaders Fund (CFI-JELF) 36624). The views expressed herein do not necessarily represent the views of the Minister of Health or the Government of Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Conjoint Health Research Ethics Board at the University of Calgary (REB18-2099).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe deidentified phenotypic and exome sequencing data will be made available upon reasonable request from any qualified investigator after institution of a material transfer agreement.